Podcasts

This episode of the Cancer Horizons podcast features Dr. Jason Porter – a medical oncologist and hematologist at the West Cancer Center and Research Institute and Director of the Lung Cancer Disease research group and is sponsored by Bristol Myers Squibb.

Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.

In addition to a breakthrough therapy designation for a lung cancer drug, this week we’ll be talking a lot about additional side effects and health conditions that may come with a cancer diagnosis, and how to manage them.

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Last week, we saw FDA approvals for new drug regimens, as well as some expert opinion about cancer vaccines

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

One cancer vaccine may still be years away from being available, a breast cancer test may be misguiding treatments for Black women and the review of two oncology regimens are being expedited by the FDA.

Here are some of the top stories from the recent Gastrointestinal Cancers Symposium as well as the Genitourinary Cancers Symposium.

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Dr. Dustin Deming, a gastrointestinal oncologist, began his own cancer journey more than a decade ago when he received a diagnosis of rectal cancer.

We take a look at the first FDA approval in the oncology space for 2024, the Lymphedema Treatment Act and more.

Last week, the FDA provided updates on two cancer therapies. In this episode, we discuss those decisions and more.

Award-winning journalist applied the same dedication that served her award-winning reporting in support of her own survival following a diagnosis of stage 4 anaplastic thyroid cancer.

The year 2024 is now underway. After a busy 2023, we’re now looking back at some of the oncology headlines from the new year.

From Jimmy Buffett's death to the chemo shortage and cannabis use in cancer care, here is a look back at some of our most popular oncology stories from 2023.

The Food and Drug Administration recently approved treatment for some patients with neuroblastoma, kidney cancer and bladder cancer. Elsewhere, a cancer vaccine made headlines for the treatment of patients with melanoma.

CURE® recently covered the 2023 American Society of Hematology Annual Meeting. In case you missed it, here is some news that came out of the conference that patients should know about.

CURE® recently covered the San Antonio Breast Cancer Symposium. In case you missed it, here is some news that came out of the conference that patients should know about.

From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.

Cervical cancer survivor Kate Weissman talks recent research on follow-up visits for patients after fertility-sparing surgery, and explains why it’s ‘something that the cervical cancer community is owed.’

Last week brought three more FDA approvals in the oncology space, as well as some research in neuropathy prevention and the diabetes-cancer connection.

Last week’s oncology headlines focused on veterans with cancer, as well as FDA regulatory decisions and an expert’s opinion on what patients need to consider when choosing a Medicare plan.

CURE® editors take a look back on last week’s major oncology headlines, from the cancer drug shortage to FDA approvals and the potential benefit of sexual activity for cervical cancer survivors.

Charlene Wexler, the Chicago-based author of the Laughter and Tears series of novels, is an ovarian cancer survivor who now has skin cancer. She told CURE® about how her son’s death from leukemia led to her re-invention as a writer.

CURE® editors discuss data from the European Society of Medical Oncology Annual Congress, and how it could lead to new therapies being approved.

Sally Joy Wolf, who has metastatic breast cancer, tells CURE about how some patients can feel adrift during the annual October “sea of pink.”

Now in its fifth edition, “The Complete Guide to Breast Reconstruction: Choosing the Best Options After Your Mastectomy” by two-time breast cancer survivor Kathy Steligo offers patients comprehensive, up-to-date information.

Kathleen Watt, whose treatment for osteosarcoma involved a decade-long process of facial reconstruction, shares her story in the memoir “Rearranged.”

"I’m on a healthy footing, and that’s pretty miraculous," said singer-songwriter Andrew McMahon, an acute lymphoblastic leukemia survivor and founder of the Dear Jack Foundation.

“I treat all of my patients like my friends and family,” said Dr. Ravi Munver of Hackensack University Medical Center, who first met Peter Kahan as his honors physics teacher more than 35 years ago.